Benign Prostatic Hyperplasia: Medical Therapy Comparison and Surgical Options

Minimally Invasive Surgical Therapies

Prostatic urethral lift (UroLift) mechanically retracts obstructing lateral lobes, improving IPSS by 11 points at 5 years while preserving sexual function[5] (no retrograde ejaculation or erectile dysfunction). Eligibility is limited to prostates 30-80 mL without a prominent median lobe. Water vapor thermal therapy (Rezum) uses convective radiofrequency-generated steam to ablate prostate tissue, with 5-year data showing sustained IPSS improvement of 47% and Qmax improvement of 50%[6], with low rates of de novo erectile dysfunction (3%) and no ejaculatory dysfunction. Aquablation (robotic waterjet ablation) guided by real-time TRUS provides size-independent tissue removal; the WATER and WATER II trials demonstrated efficacy for prostates 30-150 mL with a 2-year surgical retreatment rate of 4.3%[7].

TURP and Laser Enucleation: The Durability Standards

Transurethral resection of the prostate (TURP) remains the reference standard surgical treatment for prostates 30-80 mL, with IPSS improvement of 70% and Qmax improvement of 120% at 5 years[8]. Reoperation rates are 5-8% at 10 years. Holmium laser enucleation of the prostate (HoLEP) is size-independent, applicable even to prostates above 200 mL, with comparable symptom improvement and lower transfusion rates (0.1% versus 2-5% for TURP). The GOLIATH trial confirmed HoLEP noninferior to TURP at 2 years[9]. Selection among surgical options depends on prostate size, anatomy (median lobe presence), patient priorities regarding sexual function, operator expertise, and candidacy for anesthesia. Patients on antiplatelet therapy require perioperative medication management.

Sequencing Medical Therapy in Practice

For the patient presenting with moderate LUTS and an enlarged prostate, the practical treatment sequence begins with an alpha-blocker for rapid symptom relief — tamsulosin or silodosin for most patients, with alfuzosin as an alternative if ejaculatory dysfunction is a concern. If the prostate is significantly enlarged (above 40 mL or PSA above 1.5) or symptoms are not adequately controlled with monotherapy, adding a 5-alpha reductase inhibitor provides the additive benefit demonstrated in CombAT — 66% reduction in clinical progression — with the understanding that the combination requires 6-12 months to demonstrate full effect. For patients with persistent storage symptoms (urgency, frequency, nocturia) despite BPH-directed therapy, adding a beta-3 agonist or low-dose antimuscarinic is reasonable. The key clinical principle is that medical therapy should be optimized and given adequate time before pursuing procedural intervention — many patients referred for surgery have not had a thorough medical therapy trial.

Limitations and When to Refer

Medical therapy is effective for most patients with moderate BPH, but it has real limitations. Alpha-blockers provide symptom relief without altering disease progression. 5-ARIs slow prostatic growth but take 6-12 months for full effect and carry sexual side effect burdens that some patients find unacceptable. The newer minimally invasive procedures — UroLift preserving sexual function entirely, Rezum with only 3% de novo erectile dysfunction — offer shorter recovery times than TURP but have more limited long-term efficacy data (5-year for UroLift and Rezum versus decades for TURP). Referral to urology should occur when medical therapy fails, when complications develop (urinary retention, recurrent infections, bladder stones, renal insufficiency), or when the patient prefers procedural intervention after a fully informed discussion of the options and their tradeoffs.

References

1. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study PubMed 19962963
2. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia PubMed 14569591
3. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia PubMed 11018616
4. Silodosin therapy for lower urinary tract symptoms in men with suspected benign prostatic hyperplasia: results of an international, randomized, double-blind, placebo- and active-controlled clinical trial performed in Europe PubMed 19371887
5. Prostatic Urethral Lift: A Unique Minimally Invasive Surgical Treatment of Male Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia PubMed 30592833
6. Convective Water Vapor Energy Ablation Therapy for Benign Prostatic Hyperplasia: Durability of Treatment Outcomes from a Multicenter Study Over 4 Years PubMed 31667921
7. Aquablation vs Transurethral Resection of the Prostate: 1-Year United States Experience PubMed 30612832
8. EAU Guidelines on the Management of Non-Neurogenic Male Lower Urinary Tract Symptoms (LUTS), incl. Benign Prostatic Obstruction (BPO) PubMed 29674019
9. Holmium Laser Enucleation versus Transurethral Resection of the Prostate: Results of the 2-Year Follow-Up of a Randomized Trial (GOLIATH study) PubMed 31238345